Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units

Annals of Oncology

Volumn 9, Issue 8, 1998, Pages 885-891

  Siu, L L ^a   Attarde, G ^b   Izbicka, E ^a   Lawrence, R ^a   Cerna, C ^a   Gomez, L ^a   Davidson, K ^a   Finkle, C ^b   Marsolais, C ^b   Rowinsky, E K ^a   Von Hoff, D D ^a  

^a CTRC Institute for Drug Development   (United States)

^b Shire Canada   (Canada)

Author keywords

BCH 4556; Cloning assay; L nucleoside analogue

Indexed keywords

ANTINEOPLASTIC AGENT; NUCLEOSIDE DERIVATIVE; PACLITAXEL; TROXACITABINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG POTENCY; HUMAN; HUMAN CELL; KIDNEY CANCER; LIVER CELL CARCINOMA; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 7344255761     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008387019062     Document Type: Article

References (26)

1. Furman PA, Davis M, Liotta DC et al. The anti-hepatitis B virus activities, cytotoxicities and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2(hydroxymethyl)-1,3-oxathiolan-5-yl]-cytosine (FTC). Antimicrob Agents Chemother 1992; 36: 2686-92.
2. Coates JA, Cammack N, Jenkinson HJ et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992; 36: 202-5.
3. Mansuri MM, Farina V, Starrett JE et al. Preparation of the geometric isomers of DDC, DDA, D4C, and D4T as potential anti-HIV agents. Bioorg Med Chem Lett 1991; 1: 65-8.
4. Lin TS, Luo MZ, Liu MC et al. Antiviral activity of 2′,3′-dideoxy-B-L-5-fluorocytidine (B-L-FddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 1994; 47: 171-4.
5. Gosselin G, Mathe C, Bergogne MC et al. Enantiometric 2′,3′-deoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell cultures. C R Acad Sci Paris Sci Vie 1994; 317: 85-9.
6. Grove KL, Guo X, Liu S-H et al. Anticancer activity of β-L-dioxolane-cylidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res 1995; 55: 3008-11.
7. Kukhanova M, Liu S-H, Mozzherin D et al. L- and D-enantiomers of 2′,3′-dideoxycytidinc 5′-triphosphate analogs as substrates for human DNA polymerases. J Biol Chem 1995; 270: 23055-9.
8. Moore LE, Boudinot FD, Chu CK. Preclinical pharmacokinetics of β-L-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother Pharmacol 1997; 39: 532-6.
9. Hamburger AW, Salmon SE. Primary bioassay of human myeloma stem cell. J Clin Invest 1977; 60: 846-54.
10. Hamburger AW, Salmon SE. Primary bioassay of human myeloma stem cell. Science 1977; 197: 471.
11. Von Hoff DD, Coltman CA, Forseth B. Activity of mitoxantrone in a human tumor cloning system. Cancer Res 1981; 41: 1853.
12. Shoemaker RH, Wolpert-Defillipes MK, Kern DH et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 1985; 45: 2134-53.
13. Von Hoff DD, Huong AM, Collins J. Effect of recombinant β-interferon (r-IFN-bser) on primary human tumor colony forming units. J Interferon Res 1988; 8: 813-20.
14. Salmon SE, Liu R. Effects of granulocyte-macrophage colony stimulating factor on in vitro growth of human solid tumors. J Clin Oncol 1989; 7: 3146-50.
15. Foulke RS, Marshall MH, Trotta PP et al. In vitro assessment of the effects of granulocyte-macrophage colony stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264-7.
16. Bowlin T, Genne P, Kadhim S et al. A novel cylidine nucleoside analogue. BCH-4556, with potent activity against human anthracycline-resistant leukemia. Proc Am Assoc Cancer Res 1997; 38: 100(Abstr 668).
17. Grove KL, Cheng Y-C. Uptake and metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human proslate carcinoma DU-145 cells. Cancer Res 1996; 56: 4187-91.
18. Grove KL, Kukhanova M, Liu SH et al. Anti-tumor activity and biochemical pharmacology of L-(-)-dioxolane-c. Proc Am Assoc Cancer Res 1995; 36: 396 (Abstr 2362).
19. Rabbani SA, Harakidas P, Bowlin T et al. Prevention of prostate cancer progression and metastasis by a novel nucleoside analogue. Proc Am Assoc Cancer Res 1997; 38: 100 (Abstr 669).
20. Kadhim SA, Bowlin T, Waud WR et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β-L-dioxolane-cytidine). in human renal cell carcinoma xenograft tumor models. Cancer Res 1997; 57: 4803-10.
21. Attardo G, Kadhim S, Angers EG et al. Dose scheduling effects on the antitumor activity of BCH-4556 against human xenografts in nude mice. Proc Am Assoc Cancer Res 1997; 38: 100 (Abstr 670).
22. Sparreboom A, Van Tellingen O, Nooijen WJ et al. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs 1998; 9: 1-7.
23. Von Hoff DD. He's not going to talk about in ritro predictive assays again, is he? J Natl Cancer Inst 1990; 82: 96-101.
24. Hanauske A-R, Hilsenbeck SG, Von Hoff DD. The human tumor-cloning assay. In Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplaslic Drug Development and Pharmacology, New York: Markel Dekker 1996; 15-27.
25. Von Hoff DD, Forseth BJ, Huong M et al. Improved plating efficiencies for human tumors cloned in capillary tubes versus petri dishes. Cancer Res 1986; 46: 4012-7.
26. Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.